HDLs, immunity, and atherosclerosis

QR Code

HDLs, immunity, and atherosclerosis

Purpose of Review: HDLs possess several physiological activities that may explain their antiatherosclerotic properties. Among them, the most relevant is the ability of HDL to promote the efflux of excess cholesterol from peripheral tissues to the liver for excretion. Recent Findings: The ability of...

Full description

Bibliographic Details
Main Authors:	Norata, Giuseppe, Pirillo, A., Catapano, A.
Format:	Journal Article
Published:	Lippincott Williams & Wilkins 2011
Online Access:	http://hdl.handle.net/20.500.11937/55229

Similar Items

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

Pentraxins and atherosclerosis
by: Barbati, E., et al.
Published: (2014)

Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions
by: Ruscica, M., et al.
Published: (2017)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
by: Norata, Giuseppe, et al.
Published: (2013)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse
by: Norata, Giuseppe, et al.
Published: (2012)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

Effector memory T cells are associated with atherosclerosis in humans and animal models
by: Ammirati, E., et al.
Published: (2012)

Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population
by: Baragetti, A., et al.
Published: (2016)

IDOL N342S variant, atherosclerosis progression and cardiovascular disorders in the italian general population
by: Dhyani, A., et al.
Published: (2015)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events
by: Baragetti, A., et al.
Published: (2016)

Notch Signaling Regulates Immune Responses in Atherosclerosis
by: Vieceli Dalla Sega, F., et al.
Published: (2019)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Trained immunity and cardiovascular disease: Is it time for translation to humans?
by: Norata, Giuseppe
Published: (2018)

MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/- mice
by: Sala, F., et al.
Published: (2014)

Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis
by: Ammirati, E., et al.
Published: (2015)

Antigen-dependent and antigen-independent pathways modulate CD4 +CD28 null T-cells during atherosclerosis
by: Ammirati, E., et al.
Published: (2012)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

Novel concepts in HDL pharmacology
by: Remaley, A., et al.
Published: (2014)

Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment
by: Garetto, S., et al.
Published: (2015)

Prevalence of classical CD14++/CD16 - But not of intermediate CD14++/CD16 + monocytes in hypoalphalipoproteinemia
by: Sala, F., et al.
Published: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c4nao3p46fm2nqls3icdslljjt